Sulfur Is Part Of The Chain Or Is Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding With No Amino Nitrogen Between The Sulfur And The Aryl Ring Or Ring System Patents (Class 564/340)
-
Patent number: 9435785Abstract: Methods of analyzing purity of compositions comprising cysteamine and detecting impurities in cysteamine compositions are described.Type: GrantFiled: June 17, 2014Date of Patent: September 6, 2016Assignee: RAPTOR PHARMACEUTICALS INC.Inventors: Kathlene Powell, Ramesh Muttavarapu
-
Patent number: 9388129Abstract: Mixed inhibitors of aminopeptidase N and neprilysin are disclosed. Pharmaceutical compositions containing at least one of these compounds, used alone or in combination with morphine and derivatives thereof, endocannabinoids and inhibitors of endocannabinoid metabolism, GABA derivatives such as gabapentin or pregabalin, duloxetine or methadone, can be used as an analgesic, anxiolytic, antidepressant or anti-inflammatory.Type: GrantFiled: October 23, 2013Date of Patent: July 12, 2016Assignee: PHARMALEADSInventors: Bernard Pierre Roques, Marie-Claude Fournie-Zaluski, Hervé Poras
-
Publication number: 20150018374Abstract: Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, N-oxides, and salts thereof, wherein R1 is F, Cl or Br; R2 is H or F; and R3 is Cl or Br; and (b) at least one fungicidal compound selected from (b1) through (b13) as disclosed herein. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1, an N-oxide, or salt thereof (e.g., as a component in the aforesaid composition). Also disclosed are process intermediate compounds useful for preparing compounds of Formula 1.Type: ApplicationFiled: January 30, 2013Publication date: January 15, 2015Inventors: Andrew Edmund Taggi, Jeffrey Keith Long, James Francis Bereznak
-
Patent number: 8853146Abstract: The invention generally relates to hapten compounds comprising either (+)methamphetamine or (+)amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+)methamphetamine, (+)amphetamine, or (+)MDMA.Type: GrantFiled: April 18, 2008Date of Patent: October 7, 2014Assignee: The Board of Trustees of the University of ArkansasInventors: S. Michael Owens, Melinda Gunnell, F. Ivy Carroll
-
Patent number: 8778511Abstract: An organic light emitting device is provided. The device includes an anode and a cathode. A first organic layer is disposed between the anode and the cathode. The first organic layer is an emissive layer that includes a first organic emitting material. The device also includes a second organic layer disposed between the anode and the first organic layer. The second organic layer is a non-emissive layer. The second organic layer includes an organic small molecule hole transport material having a concentration of 50 to 99 wt %, and an organic small molecule electron transport material having a concentration of 0.1 to 5 wt %. Other materials may be present.Type: GrantFiled: October 1, 2009Date of Patent: July 15, 2014Assignee: Universal Display CorporationInventors: Vadim Adamovich, Brian D'Andrade, Michael S. Weaver
-
Publication number: 20140081032Abstract: Processes for the preparation of certain isoindole compounds, and isotopologues thereof, are provided. In some embodiments, the processes comprise catalytic assymetrical hydrogenation with hydrogen gas or deuterium gas in a solvent containing exchangeable proton or deuterium for proton-deuterium exchange.Type: ApplicationFiled: September 13, 2013Publication date: March 20, 2014Applicant: Celgene CorporationInventors: Terrence J. Connolly, Alexander L. Ruchelman, Kelvin H.Y. Yong, Chengmin Zhang
-
Publication number: 20140058070Abstract: There are provided compounds and methods for amidating the C-terminus of a polypeptide. The method include reacting a polypeptide which includes a C-terminal thioester or C-terminal selenoester with any one of a defined set of auxiliary molecules under conditions suitable to produce a polypeptide adduct which includes the auxiliary molecule chemically bound at the C-terminal of the polypeptide. In the subsequent step, the auxiliary molecule is removed from the C-terminal of the polypeptide adduct under conditions suitable to produce an amidated polypeptide.Type: ApplicationFiled: September 8, 2011Publication date: February 27, 2014Applicant: AstraZeneca Pharmaceuticala LPInventors: Chengzao Sun, Behrouz Bruce Forood, Gary Luo, Soumitra S. Ghosh
-
Publication number: 20130217918Abstract: Provided herein are new processes for the preparation of aminosulfone intermediates for the synthesis of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, which is useful for preventing or treating diseases or conditions related to an abnormally high level or activity of TNF-?. Further provided herein are processes for the commercial production of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine.Type: ApplicationFiled: February 20, 2013Publication date: August 22, 2013Applicant: CELGENE CORPORATIONInventor: CELGENE CORPORATION
-
Patent number: 8247608Abstract: The invention relates to novel compounds of formula (I): H2N—CH(R1)—CH2—S—S—CH2—CH(R2)—CONH—R5, wherein R1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5 or 6 atom heterocycle; R5 is a CH(R3)—COOR4 radical, wherein R3 is hydrogen, an OH or OR group, a saturated hydrocarbon group, a phenyl or benzyl radical and OR4 is hydrophile ester, or 5 or 6 membered heterocycle comprising several heteroatoms selected from a group consisting of nitrogen, sulphur and oxygen, with at least two nitrogene atoms, wherein said heterocycle is substitutable by an alkyl C1-C6, phenyl or benzyl radical.Type: GrantFiled: October 24, 2006Date of Patent: August 21, 2012Assignee: PharmaleadsInventors: Bernard Roques, Marie-Claude Fournie-Zaluski
-
Patent number: 8247609Abstract: The invention relates to novel compounds of formula (I): H2N—CH(R1)—CH2—S—S—CH2—CH(R2)—CONH—R5, wherein R1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5 or 6 atom heterocycle; R5 is a CH(R3)—COOR4 radical, wherein R3 is hydrogen, an OH or OR group, a saturated hydrocarbon group, a phenyl or benzyl radical and OR4 is hydrophile ester, or 5 or 6 membered heterocycle comprising several heteroatoms selected from a group consisting of nitrogen, sulphur and oxygen, with at least two nitrogene atoms, wherein said heterocycle is substitutable by an alkyl C1-C6, phenyl or benzyl radical.Type: GrantFiled: June 26, 2008Date of Patent: August 21, 2012Assignee: PharamleadsInventors: Bernard Roques, Marie-Claude Fournie-Zaluski
-
Patent number: 8242310Abstract: Processes for synthesizing aminosulfone compounds are provided. Aminosulfone compounds obtained using methods provided herein are useful in production or synthesis of isoindoline based PDE 4 modulators.Type: GrantFiled: September 9, 2009Date of Patent: August 14, 2012Assignee: Celgene CorporationInventors: Manohar T. Saindane, Chuansheng Ge
-
Publication number: 20100168475Abstract: Processes for synthesizing aminosulfone compounds are provided. Aminosulfone compounds obtained using methods provided herein are useful in production or synthesis of isoindoline based PDE 4 modulators.Type: ApplicationFiled: September 9, 2009Publication date: July 1, 2010Inventors: Manohar T. SAINDANE, Chuansheng GE
-
Patent number: 7723385Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.Type: GrantFiled: February 25, 2009Date of Patent: May 25, 2010Assignee: GlaxoSmithKline LLCInventors: Philip Stewart Turnbull, Rodolfo Cadilla, David John Cowan, Andrew Lamont Larkin, Istvan Kaldor, Eugene Lee Stewart
-
Patent number: 7514470Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.Type: GrantFiled: March 3, 2005Date of Patent: April 7, 2009Assignee: SmithKline Beecham CorporationInventors: Philip Stewart Turnbull, Rodolfo Cadilla, David John Cowan, Andrew Lamont Larkin, Istvan Kaldor, Eugene Lee Stewart
-
Patent number: 7385064Abstract: Disclosed are compounds having the following formula: in which Z11 is selected from a substituted or unsubstituted saturated adamantyl or other polycyclic group and a substituted or unsubstituted branched acyclic group containing at least 5 carbon atoms at least one of which is a tertiary carbon; and in which Z12 is a cyclic imide. Methods of using these compounds as chiral catalysts for carbenoid reactions and for enantioselective C—H aminations are also described.Type: GrantFiled: November 30, 2006Date of Patent: June 10, 2008Assignee: The Research Foundation of State University of New YorkInventors: Huw M. L. Davies, Ravisekhara P. Reddy
-
Patent number: 7351389Abstract: Novel metal-chelate complexes comprising aminocarboxylate ligands including substituted aromatic amide moieties, such as those having the formula wherein R13, A1, R1 and R2 are as defined herein, are disclosed.Type: GrantFiled: October 13, 2004Date of Patent: April 1, 2008Assignee: Bracco International B.V.Inventors: Radhakrishna K. Pillai, Sang I. Kang, Edmund R. Marinelli, Ramachandran S. Ranganathan, Michael F. Tweedle
-
Patent number: 7297820Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: September 6, 2005Date of Patent: November 20, 2007Assignee: Trustees of The University of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang
-
Patent number: 7179926Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.Type: GrantFiled: July 25, 2005Date of Patent: February 20, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Yazhong Huang, Shuanghua Hu, Andrew P. Degnan
-
Patent number: 7109343Abstract: Compounds having the formula: are disclosed. M1 and M2 are the same or different and are transition metal atoms or ions; Z2 and Z3, independently, are the atoms necessary to complete a 3–12 membered heterocyclic ring; Z1 is an alkylene or arylene group; Q1 and Q2 are the same or different and are electron withdrawing groups; L1 and L3, taken together, represent —O—CR13—O—; L2 and L4, taken together, represent —O—CR14—O—; and R13 and R14 are the same or different and are selected from the group consisting of alkyl groups and aryl groups or R13 and R14 represent alkylene or arylene groups that are directly or indirectly bonded to one another. Methods for making such compounds are also disclosed, as are intermediates which can be used in their preparation. Also disclosed are methods for carrying out C—H insertion reactions using bis-transition metal catalysts, such as the above compounds. Procedures for preparing d-threo methylphenidate, tolterodine, CDP-840, nominfensine, and sertraline, are described.Type: GrantFiled: April 5, 2004Date of Patent: September 19, 2006Assignee: The Research Foundation of State University of New YorkInventor: Huw M. L. Davies
-
Patent number: 7045649Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention may include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.Type: GrantFiled: September 22, 2003Date of Patent: May 16, 2006Assignee: Aventis Pharma Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Patent number: 7015208Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention may include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.Type: GrantFiled: November 4, 2004Date of Patent: March 21, 2006Assignee: Aventis Pharma Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Patent number: 6958419Abstract: An alkynyl S,N-acetal derivative of the present invention is represented by the following structural formula: In the structural formula, R1 represents a hydrogen atom, an alkyl group, an aryl group, an alkenyl group, a silyl group, or an alkynyl group; each of R2 and R3 represents an alkyl group or an allyl group; and R4 represents an alkyl group. The alkynyl S,N-acetal derivative, which is a novel compound, is useful as a raw material of propargylamine.Type: GrantFiled: December 11, 2003Date of Patent: October 25, 2005Assignee: Gifu UniversityInventors: Toshiaki Murai, Yuichiro Mutoh
-
Patent number: 6919380Abstract: Derivatives of C2-substituted indan-1-ol compounds of formula I: its physiologically acceptable salts, and its physiologically functional derivatives for the prophylaxis or treatment of obesity are disclosed herein. Compositions comprising the same, methods for preparing the instant compounds, and methods for reducing weight in mammals and for the prophylaxis or treatment of obesity are also described.Type: GrantFiled: October 27, 2003Date of Patent: July 19, 2005Assignee: Aventis Pharma Deutschland GmbH.Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Publication number: 20040254226Abstract: Pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound with the formula: 1Type: ApplicationFiled: May 13, 2004Publication date: December 16, 2004Applicant: Syrrx, Inc.Inventors: Jun Feng, Stephen L. Gwaltney, Jeffrey A. Stafford, Michael B. Wallace, Xiao-Yi Xiao, Zhiyuan Zhang
-
Publication number: 20040242654Abstract: The present invention provides diaryl ether derivatives that exhibit significant immunosuppressive effects with less side effects.Type: ApplicationFiled: March 22, 2004Publication date: December 2, 2004Inventors: Yasushi Kohno, Naoki Ando, Takahiro Tanase, Kazuhiko Kuriyama, Satoru Iwanami, Shinji Kudou
-
Patent number: 6812256Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.Type: GrantFiled: October 27, 2003Date of Patent: November 2, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Patent number: 6762326Abstract: Embodiments of the invention relate to C2-substituted indan-1-ones and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.Type: GrantFiled: August 30, 2002Date of Patent: July 13, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Publication number: 20040127546Abstract: Compounds of the general formula (I): 1Type: ApplicationFiled: January 22, 2004Publication date: July 1, 2004Applicant: ASAHI KASEI PHARMA CORPORATIONInventors: Shunichi Ikuta, Shiro Miyoshi, Kohei Ogawa
-
Publication number: 20040068016Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives.Type: ApplicationFiled: September 22, 2003Publication date: April 8, 2004Applicant: AVENTIS PHARMA DEUTSCHLAND GMBHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Publication number: 20040063765Abstract: The present invention relates to the use of compounds of the general Formula (I): 1Type: ApplicationFiled: May 6, 2003Publication date: April 1, 2004Applicant: 4 SC AGInventors: Aldo Ammendola, Katharina Aulinger-Fuchs, Astrid Gotschlich, Bernd Kramer, Martin Lang, Wael Saeb, Udo Sinks, Andreas Wuzik
-
Patent number: 6686397Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed: Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.Type: GrantFiled: August 29, 2002Date of Patent: February 3, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Patent number: 6670401Abstract: Polysubstituted indan-1-ol compounds, methods for their preparation; and methods for their use are disclosed herein. In particular, the invention relates to polysubstituted indan-1-ol compounds of the formula I and their physiologically acceptable salts. The compounds are useful, for example, as anorectics.Type: GrantFiled: August 30, 2002Date of Patent: December 30, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Patent number: 6667345Abstract: Derivatives of C2-substituted indan-1-ol compounds of the formula I: its physiologically acceptable salts, and its physiologically functional derivatives for the prophylaxis or treatment of obesity are disclosed herein. Compositions comprising the same, methods for preparing the instant compounds, and methods for reducing weight in mammals and for the prophylaxis or treatment of obesity are also described.Type: GrantFiled: August 29, 2002Date of Patent: December 23, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Publication number: 20030232823Abstract: A compound of Formula (I) 1Type: ApplicationFiled: January 3, 2003Publication date: December 18, 2003Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Rajashekhar Betageri, David S. Thomson, Yan Zhang, Renee Michele Zindell
-
Publication number: 20030153781Abstract: The present invention discloses aminothiol compounds and acylated derivatives thereof, which respectively have general formula I and formula II wherein R1-R6 are substitutable ligands. Such compounds can perform as superior catalysts in asymmetric addition reactions of organic zinc and aldehyde. According to the present invention, the compounds is needed only less than 0.02% of main reactants to obtain enantioselectivity higher than 99% enantiomeric excess, whereby the asymmetric reactions can become very economic.Type: ApplicationFiled: January 8, 2002Publication date: August 14, 2003Inventors: Teng-Kuei Yang, Nan-Kuang Chen, To Liu
-
Publication number: 20030105161Abstract: There are provided novel compounds of formula (I), 1Type: ApplicationFiled: August 22, 2002Publication date: June 5, 2003Inventors: Tim Birkinshaw, David Cheshire, Antonio Mete
-
Publication number: 20030100796Abstract: A process for producing &agr;-aminohalomethyl ketones or N-protected &agr;-aminohalomethyl ketones from specified 3-oxazolidin-5-one derivatives via 5-halomethyl-5-hydroxy-3-oxazolidine derivatives. By this process, &agr;-aminohalomethyl ketones and compounds relating to them can be obtained efficiently and economically in industrial scale.Type: ApplicationFiled: November 8, 2002Publication date: May 29, 2003Applicant: AJINOMOTO CO., INC.Inventors: Tomoyuki Onishi, Naoko Hirose, Takayuki Suzuki, Takashi Nakano, Masakazu Nakazawa, Kunisuke Izawa
-
Patent number: 6410746Abstract: Compounds having the formula: are disclosed. M1 and M2 are the same or different and are transition metal atoms or ions; Z2 and Z3, independently, are the atoms necessary to complete a 3-12 membered heterocyclic ring; Z1 is an alkylene or arylene group; Q1 and Q2 are the same or different and are electron withdrawing groups; L1 and L3, taken together, represent —O—CR13—O—; L2 and L4, taken together, represent —O—CR14—O—; and R13 and R14 are the same or different and are selected from the group consisting of alkyl groups and aryl groups or R13 and R14 represent alkylene or arylene groups that are directly or indirectly bonded to one another. Methods for making such compounds are also disclosed, as are intermediates which can be used in their preparation. Also disclosed are methods for carrying out C—H insertion reactions using bis-transition metal catalysts, such as the above compounds.Type: GrantFiled: March 8, 2000Date of Patent: June 25, 2002Assignee: Research Foundation of State University of New York, TheInventor: Huw M. L. Davies
-
Publication number: 20020013498Abstract: Disclosed is a process for selectively reducing a nitrile containing organic compound that also contains a sulfone moiety, the nitrile being reduced to a primary amine.Type: ApplicationFiled: April 27, 2001Publication date: January 31, 2002Inventors: Jack ChanKou Hwang, Eugene Tarlton, Anthony D. Piscopio
-
Patent number: 6281379Abstract: This invention to provide a process for producing an optically active threo-phenylnorstatin derivative which does not require a toxic cyanating agent or a costly reagent, or a complicated procedure, and can be practiced on a commercial scale. This invention is directed to a process for producing a &bgr;-amino-&agr;-hydroxy acid derivative which comprises treating either a &ggr;-amino-&bgr;-keto sulfoxide derivative with a halogenating agent to produce a &ggr;-amino-&agr;-halo-&bgr;-keto sulfoxide derivative, treating the same with an acid and an alcohol to produce a &bgr;-amino-&agr;-keto ester derivative or &bgr;-amino-&agr;-keto acid derivative, and followed by reducing.Type: GrantFiled: May 26, 2000Date of Patent: August 28, 2001Assignee: Kaneka CorporationInventors: Akio Fujii, Masanobu Sugawara, Kenji Inoue
-
Patent number: 6255496Abstract: Selective inhibitors of the cPLA2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases.Type: GrantFiled: April 27, 1999Date of Patent: July 3, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Jacques Banville, Yonghua Gai, Graham Johnson, Fred Christopher Zusi, James R. Burke
-
Patent number: 6150558Abstract: The invention relates to novel bis-o-aminophenols, and bis-o-aminothiophenols of the following structure: ##STR1## where A.sup.1 to A.sup.6 are--independently of one another--H, F, CH.sub.3, CF.sub.3, OCH.sub.3, OCF.sub.3, CH.sub.2 CH.sub.3, CF.sub.2 CF.sub.3, OCH.sub.2 CH.sub.3 or OCF.sub.2 CF.sub.3, where at least one of the radicals A.sup.1 to A.sup.6 must be F or an F-containing group; T is O or S, and m is 0 or 1; and Z is a carbocyclic or heterocyclic aromatic radical.Type: GrantFiled: September 24, 1998Date of Patent: November 21, 2000Assignee: Siemens AktiengesellschaftInventors: Recai Sezi, Michael Keitmann
-
Patent number: 6022906Abstract: Compounds of the formulae I, II, III and IV ##STR1## wherein Ar for example is a phenyl, biphenyl or benzoylphenyl group, which is unsubstituted or substituted; Ar.sub.1, for example, has the same meanings as Ar; Ar.sub.2 is inter alia phenyl; X may be a direct bond; Y hydrogen, etc.; R.sub.1 and R.sub.2 for example C.sub.1 -C.sub.8 alkyl; R.sub.3 inter alia hydrogen or C.sub.1 -C.sub.12 alkyl; R.sub.4 is inter alia C.sub.1 -C.sub.12 alkyl; or R.sub.3 and R.sub.4 together are C.sub.3 -C.sub.7 alkylene; R.sub.5 is for example C.sub.1 -C.sub.6 alkylene; and Z is a divalent radical; provided that at least one of the radicals Ar, Ar.sub.1, Ar.sub.2, Ar.sub.3, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 or Y is substituted by 1 to 5 SH groups, or provided that Y contains at least one --SS-- group, are photoinitiators for the polymerization of ethylenically unsaturated compounds.Type: GrantFiled: December 1, 1997Date of Patent: February 8, 2000Assignee: Ciba Specialty Chemicals CorporationInventors: Masaki Ohwa, Hitoshi Yamoto, Jean-Luc Birbaum, Hiroko Nakashima, Akira Matsumoto, Hidetaka Oka
-
Patent number: 5952316Abstract: 2-Amino-1,3-propanediol compounds of the formula (I) ##STR1## wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these compounds as active ingredients.The 2-amino-1,3-propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.Type: GrantFiled: August 14, 1997Date of Patent: September 14, 1999Assignees: Yoshitomi Pharmaceutical Industries, Ltd., Taito Co., Ltd.Inventors: Tetsuro Fujita, Shigeo Sasaki, Masahiko Yoneta, Tadashi Mishina, Kunitomo Adachi, Kenji Chiba
-
Patent number: 5925332Abstract: Compounds useful in radioimaging and radiochemotherapy as it particularly relates to the treatment and location of malignant melanomas and other pigmenting disorders, as well as novel acyl derivatives of phenolic thioester amines and their use in compositions for blocking melanin synthesis in human or animal melanocyte cells.Type: GrantFiled: March 15, 1995Date of Patent: July 20, 1999Assignee: The Governors of the University of AlbertaInventor: Kowichi Jimbow
-
Patent number: 5789448Abstract: Disclosed is a benzoylethylene derivative represented by the following formula (I) or a salt thereof. ##STR1## R.sup.1 to R.sup.5 : a hydrogen atom, --OR.sup.9 (R.sup.9 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc.), etc.,R.sup.6 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc.,R.sup.7 : a hydrogen atom, a cyano group, a C.sub.1 -C.sub.5 alkyl group, --SO.sub.q R.sup.15 (q: 0, 1, 2, R.sup.15 : a thienyl group, a phenyl group, etc.) etc.,R.sup.8 : a cyano group, --CR.sup.22 R.sup.23 X (R.sup.22, R.sup.23 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc., X: --NR.sup.24 R.sup.25 (R.sup.24, R.sup.25 : a C.sub.1 -C.sub.5 alkyl group, etc., an alkylene group by combining, etc.)), etc.The benzoylethylene derivative of the present invention has potent tyrosine kinase inhibiting activity and cancer cell growth inhibiting activity. The tyrosine kinase inhibitor of the present invention is useful as a carcinostatic agent.Type: GrantFiled: June 25, 1996Date of Patent: August 4, 1998Assignee: Mitsubishi Chemical CorporationInventors: Yasunori Kitano, Haruki Inokawa, Hisao Takayanagi, Tamaki Yano, Hiroe Umeki, Hiroto Hara
-
Patent number: 5756068Abstract: Compounds useful in radioimaging and radiochemotherapy as it particularly relates to the treatment and location of malignant melanomas and other pigmenting disorders, as well as novel acyl derivatives of phenolic thioester amines and their use in compositions for blocking melanin synthesis in human or animal melanocyte cells.Type: GrantFiled: August 27, 1996Date of Patent: May 26, 1998Assignee: The Governors of the University of AlbertaInventor: Kowichi Jimbow
-
Patent number: 5719176Abstract: A 2-amino-1,3-propanediol compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, and an immunosuppressant containing the same as the active ingredient. In said formula R represents optionally substituted linear or branched carbon chain, optionally substituted aryl or optionally substituted cycloalkyl; and R.sup.2, R.sup.3, R.sup.4 and R.sup.5, which may be the same or different from one another, represent each hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl. The compound is immunodepressant and useful as an inhibitor against rejection in organ or bone marrow transplantation, as a preventive or remedy for autoimmune diseases and so forth, or a reagent in the medical and pharmaceutical fields.Type: GrantFiled: October 2, 1996Date of Patent: February 17, 1998Assignees: Yoshitomi Pharmaceutical Industries, Ltd., Taito Co., Ltd.Inventors: Tetsuro Fujita, Shigeo Sasaki, Masahiko Yoneta, Tadashi Mishina, Kunitomo Adachi, Kenji Chiba
-
Patent number: 5674909Abstract: Compounds of formula ##STR1## wherein R, R', R", R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, X, Y, m, n and p have the meanings reported in the description;and their pharmaceutically acceptable salts are described.The compounds of formula I are useful in the treatment of arterial hypertension and congestive heart failure, of renal failure, of peripheral arteriopathies, of cerebrovascular insufficiencies and of ischemic cardiopathy.Type: GrantFiled: June 6, 1995Date of Patent: October 7, 1997Assignee: Zambon GroupInventors: Stefania Montanari, Paolo Cavalleri, Cristina Fraire, Gian Carlo Grancini, Mauro Napoletano, Francesco Santangelo
-
Patent number: 5639887Abstract: Compounds of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are herein described, A is a straight or branched (C.sub.2 -C.sub.12)alkyl or a phenyl moiety and B is a moiety of the formula: ##STR2## The compounds are effective in potentiating the activity of chemotherapeutic anti-cancer agents by increasing the sensitivity of multi-drug resistant cells to such chemotherapeutic agents.Type: GrantFiled: May 25, 1995Date of Patent: June 17, 1997Assignee: American Cyanamid CompanyInventors: Dennis Powell, Rolf Paul, William A. Hallett, Dan M. Berger, Minu D. Dutia